The U.S. Food and Drug Administration recently issued its final approval for Mylan’s Abbreviated New Drug Application for its Exemestane Tablets in a 25mg dosage, which are a generic version of Pfizer’s Aromasin tablets. Read More »

Regeneron Pharmaceutical Inc. and Sanofi recently presented the results of their one-year Phase 3 CHRONOS study, showing that investigational drug DUPIXENT combined with topical corticosteroids achieved better results in treating uncontrolled moderate-to-severe atopic dermatitis than TCS alone. Read More »

Chinese authorities recently approved Pfizer China’s oral Janus kinase inhibitor XELJANZ, with active ingredient tofacitinib citrate, indicated for treating adults with moderate to severely active rheumatoid arthritis. Read More »

Amgen’s recent Phase 3 study of the effects of Repatha on patients who receive apheresis for low-density lipoprotein cholesterol showed a promising reduction in the need for the recurring procedure. Read More »

The U.S. Food and Drug Administration has accepted a supplemental New Drug Application for Auryxia tablets from Keryx Biopharmaceuticals Inc., a company specializing in innovative medicines to fight renal disease. Read More »

Regeneron and Sanofi are set to present new data from the Phase 3 Praluent (alirocumab) injection clinical trial program at this weekend’s American College of Cardiology Scientific Sessions (ACC 17) in Washington, D.C. Read More »

Pfizer Inc.'s combination antibiotic Zavicefta is now available in the United Kingdom and Germany for the treatment of Gram-negative bacterial infections requiring hospitalization. Read More »

In honor of Multiple Sclerosis Awareness Month, Acorda Therapeutics recently launched a new Alexa skill called MS Awareness Facts that will help Amazon Alexa users learn more about the chronic disease and its symptoms.   Read More »

Abbot recently announced that the U.S. Food and Drug Administration (FDA) approved its FlexAbility Ablation Catheter. Read More »

Acura Pharmaceuticals Inc. and MainPointe Pharmaceuticals LLC recently entered a licensing agreement that will give MainPointe exclusive marketing rights for NEXAFED and NEXAFED Sinus in the United States and Canada. Read More »

Diplomat Pharmacy Inc. recently announced that it will dispense KISQALI as a first-line treatment for postmenopausal women with serious forms of breast cancer. Read More »

Amgen's positive results from a planned overall survival interim analysis of the Phase 3 head-to-head ENDEAVOR trial. Read More »

Amgen recently announced positive data from the Phase 3 '482 study, which is the largest international multiple myeloma trial ever conducted. Read More »

Allergan and Editas Medicine have entered a strategic research and development alliance that gives Allergan exclusive access and the option to license up to five of Editas Medicine’s genome-editing ocular programs. Read More »

Sen. Ron Wyden (D-OR) last week introduced legislation that he says would increase pricing "transparency" among pharmacy benefit managers.  Read More »

Mylan N.V. recently announced that it settled a case relating to patents for Herceptin, from Genentech Inc. and F. Hoffman-La Roche Ltd., giving Mylan global licenses for its trastuzumab product. Read More »

Amgen recently announced the results of the Repatha (evolocumab) cognitive function trial that examined cognitive function for 1,974 patients enrolled in the Repatha cardiovascular outcomes study. Read More »

Alkermes PLC will present data for the two-month dosing option of ARISTADA (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia at the 16th International Congress on Schizophrenia Research in San Diego Friday through Monday. Read More »

Sanofi Healthcare, the company behind Xyzal Allergy 24HR, recently announced the results of an allergy-related social experiment involving 160 participants who wore wearable devices for 30 days to track sleep and activity. Read More »

Biologics Inc., an oncology pharmacy services company owned by McKesson Specialty Health, was selected by Novartis to be a specialty pharmacy provider for KISQALI (ribociclib). Read More »